David Nutt | |
|---|---|
 Professor David Nutt, February 2020 | |
| Born | (1951-04-16)16 April 1951 (age 74) Bristol, England, United Kingdom |
| Citizenship | British |
| Education | Bristol Grammar School |
| Alma mater | Downing College, Cambridge |
| Known for | FoundingDrug Science[1] Controversial removal from theAdvisory Council on the Misuse of Drugs[2] Performing the first MRI of a human brain under the influence ofLSD[3] Ecstasy controversy[4] |
| Scientific career | |
| Institutions | Drug Science Imperial College London University of Cambridge University of Oxford University of Bristol Guy's Hospital Advisory Council on the Misuse of Drugs (ACMD) Independent Scientific Committee on Drugs (ISCD) The European Brain Council |
| Thesis | The effect of convulsions and drugs on seizure susceptibility in rats (1982) |
| Website | drugscience |
David John Nutt (born 16 April 1951) is an Englishneuropsychopharmacologist specialising in the research ofdrugs that affect thebrain and conditions such asaddiction,anxiety, andsleep.[6] He is the chairman ofDrug Science, a non-profit which he founded in 2010 to provide independent, evidence-based information on drugs.[7] In 2019 he co-founded the company GABAlabs and its subsidiary SENTIA Spirits which research and market alternatives to alcohol. Until 2009, he was aprofessor at theUniversity of Bristol heading their Psychopharmacology Unit.[8] Since then he has been theEdmond J Safra chair in Neuropsychopharmacology atImperial College London and director of the Neuropsychopharmacology Unit in the Division of Brain Sciences there.[9] Nutt was a member of theCommittee on Safety of Medicines, and was President of theEuropean College of Neuropsychopharmacology.[10][11][12]
Nutt completed his secondary education atBristol Grammar School and then studied medicine atDowning College, Cambridge, graduating in 1972. In 1975, he completed his clinical training atGuy's Hospital.[13]
He worked as a clinical scientist at theRadcliffe Infirmary from 1978 to 1982 where he carried out basic research into the function of thebenzodiazepine receptor/GABA ionophore complex, the long-term effects of BZ agonist treatment and kindling with BZ partial inverse agonists. This work culminated in a ground-breaking paper inNature in 1982[14] which described the concept of inverse agonism (using his preferred term, "contragonism") for the first time. From 1983 to 1985, he lectured inpsychiatry at theUniversity of Oxford. In 1986, he was theFogarty visiting scientist at theNational Institute on Alcohol Abuse and Alcoholism inBethesda, MD, outsideWashington, D.C. Returning to the UK in 1988, he joined theUniversity of Bristol as director of the Psychopharmacology Unit. In 2009, he then established the Department of Neuropsychopharmacology and Molecular Imaging at Imperial College, London, taking a new chair endowed by the Edmond J Safra Philanthropic Foundation.[13] He is an editor of theJournal of Psychopharmacology,[15] and in 2014 was elected president of theEuropean Brain Council.[16]
In 2007 Nutt published a study on the harms of drug use inThe Lancet.[17] Eventually, this led to his dismissal from his position in theAdvisory Council on the Misuse of Drugs (ACMD;seegovernment positions below). Subsequently, Nutt and a number of his colleagues who had resigned from the ACMD founded theIndependent Scientific Committee on Drugs, later renamed asDrug Science.[18]
Nutt has since produced numerous prominent reports on drug policy through Drug Science, while launching campaigns of support for evidence-based drug policy; including Project Twenty21, Medical Cannabis Working Group, and the Medical Psychedelics Working Group.[7] In 2013, Drug Science launched a peer-reviewed journal -Journal of Drug Science, Policy and Law - for which Nutt was appointed Editor.[19] Nutt also hosts theDrug Science Podcast, in which he engages drug policy experts, policy-makers, and scientists on the topics of drugs and drug policy.[20]
Nutt is the deputy head of the Centre for Psychedelic Research at Imperial College London.[21] He and his team have published research intopsilocybin for treatment-resistant depression, as well as neuroimaging studies investigating psilocybin,MDMA,LSD, andDMT.[22]
In November 2010, Nutt published a study inThe Lancet - co-authored withLes King and Lawrence Phillips, on behalf of the Independent Committee on Drug Science - which ranked the harm done to individual users and broader society by a range of licit and illicit drugs.[23] Owing in part to criticism of the 2007 study for arbitrary weighting of factors,[18][24] the 2010 study employed amultiple-criteria decision analysis in its procedure to support their conclusion that alcohol is more harmful to society than heroin andcrack (cocaine), whereas heroin, crack, andmethamphetamine are most harmful to individuals.[23] Nutt has also published popular-level articles on these findings in newspapers and print media for the general public,[25] which have been met with to public disagreement from other researchers.[26]
Nutt continues to campaign for changing UK drug laws to facilitate greater research opportunities.[27][28][29][30]
Building on his extensive research on the role of GABA in the brain, and the psychopharmacology of alcohol, since 2014 Nutt has spoken publicly about his desire to bringing-to-market a compound which could act as a "safer" replacement to alcohol and mimic some of its effects – namely, "conviviality" – by affecting theGABA receptor[31] without the negative health impacts of alcohol. Nutt has named the compound "Alcarelle", but has not yet disclosed the exact chemical composition; preliminary tests employed abenzodiazepine derivative, with later adaptations aimed at improving efficacy and reducing abuse potential.
In 2018 Nutt's company GABALabs (previously called "Alcarelle") lodged patents branded as "Alcarelle,"[32] for several new compounds proposing to more closely mimic the desired "conviviality" of alcohol.[33][34] As of October 2019, no research has been published regarding the efficacy, safety, or long-term health impacts of these compounds, nor have they been made publicly available to consumers.
In January 2021, the science team at GABA Labs released-to-market a plant-based functional alcohol alternative, under the brand "Sentia,"[35] and advertised as a "botanical spirit" reported to reproduce the relaxed and social effects typically associated with the consumption of alcoholic beverages.[36]
In collaboration withAmanda Feilding and theBeckley Foundation, Nutt is investigating the effects of psychedelics on cerebral blood flow.[38][39][40][41][42]
Nutt previously worked as an advisor to theMinistry of Defence,Department of Health, and theHome Office.[13]
He served on theCommittee on Safety of Medicines where he participated in an inquiry into the use ofSSRIanti-depressants in 2003. The inquiry drew criticism for Nutt's participation, based on potential conflict-of-interest over his financial involvement inGlaxoSmithKline, which led to his withdrawal from discussions of the drugparoxetine.[43] In January 2008 he was appointed as chairman of theAdvisory Council on the Misuse of Drugs (ACMD), having previously served as Chair of the Technical Committee of the ACMD for seven years.[6]
.svg)
As ACMD chairman, government ministers have repeatedly clashed with Nutt over conflicting opinions regarding drug harm and drug classification. In January 2009, Nutt published an editorial in theJournal of Psychopharmacology ("Equasy – An overlooked addiction with implications for the current debate on drug harms") in which the risks associated withhorse riding (1 serious adverse event every ~350 exposures) were compared to those of taking ecstasy (1 serious adverse event every ~10,000 exposures).[4]
The wordequasy is a portmanteau ofecstasy andequestrianism (based onLatinequus, 'horse'). Nutt toldThe Daily Telegraph that his intention was "to get people to understand that drug harm can be equal to harms in other parts of life".[45] In 2012, he explained to theUK Home Affairs Committee that he chose riding as the "pseudo-drug" in his comparison after being consulted by a patient with irreversible brain damage caused by a fall from a horse. He discovered that riding was "considerably more dangerous than [he] had thought ... popular but dangerous" and "something ... that young people do".[46]
Equasy has been frequently referred to in later discussions ofdrug harmfulness anddrug policies.[47][48][49][50][51]
The issue of the mismatch between lawmakers'classification ofrecreational drugs, in particular that ofcannabis, and scientific measures of their harmfulness surfaced again in October 2009, after the publication of a pamphlet[52] containing a lecture Nutt had given to the Centre for Crime and Justice Studies at King's College London in July 2009. In this, Nutt repeated his view that illicit drugs should be classified according to the actual evidence of the harm they cause, and presented an analysis in which nine 'parameters of harm' (grouped as 'physical harm', 'dependence', and 'social harms') revealed that alcohol or tobacco were more harmful than LSD, ecstasy or cannabis. In this ranking, alcohol came fifth behind heroin, cocaine, barbiturates and methadone, and tobacco ranked ninth, ahead of cannabis, LSD and ecstasy, he said. In this classification, alcohol and tobacco appeared as Class B drugs, and cannabis was placed at the top of Class C. Nutt also argued that taking cannabis created only a "relatively small risk" of psychotic illness,[53] and that "the obscenity of hunting down low-level cannabis users to protect them is beyond absurd".[54] Nutt objected to the recent re-upgrading (after 5 years) of cannabis from a Class C drug back to a Class B drug (and thus again on a par with amphetamines), considering it politically motivated rather than scientifically justified.[44] In October 2009 Nutt had a public disagreement with psychiatristRobin Murray in the pages ofThe Guardian about the dangers of cannabis in triggeringpsychosis.[26]
Following the release of this pamphlet, Nutt was dismissed from his ACMD position by theHome Secretary,Alan Johnson. Explaining his dismissal of Nutt, Johnson wrote in a letter toThe Guardian that "[Nutt] was asked to go because he cannot be both a government adviser and a campaigner against government policy. [...] As for his comments about horse riding being more dangerous than ecstasy, which you quote with such reverence, it is of course a political rather than a scientific point."[55] Responding inThe Times, Professor Nutt said: "I gave a lecture on the assessment of drug harms and how these relate to the legislation controlling drugs. According to Alan Johnson, the Home Secretary, some contents of this lecture meant I had crossed the line from science to policy and so he sacked me. I do not know which comments were beyond the line or, indeed, where the line was [...]".[56] He maintains that "the ACMD wassupposed to give advice on policy".[57]
In the wake of Nutt's dismissal, Dr Les King, a part-time advisor to the Department of Health, and the senior chemist on the ACMD, resigned from the body.[58] His resignation was soon followed by that of Marion Walker, Clinical Director of Berkshire Healthcare NHS Foundation Trust's substance misuse service, and theRoyal Pharmaceutical Society's representative on the ACMD.[59]
The Guardian revealed that Alan Johnson ordered what was described as a 'snap review' of the 40-strong ACMD in October 2009. This, it was said, would assess whether the body is "discharging the functions" that it was set up to deliver and decide if it still represented value for money for the public. The review was to be conducted byDavid Omand.[60] Within hours of that announcement, an article was published online byThe Times arguing that Nutt's controversial lecture actually conformed to government guidelines throughout.[61] This issue was further publicised a week later when Liberal Democrat science spokesman DrEvan Harris, MP, attacked the Home Secretary for apparently having misled Parliament and the country in his original statement about Nutt's dismissal.[62]
John Beddington, theChief Scientific Adviser to the UK Government stated that he agreed with the views of Professor Nutt on cannabis. When asked if he agreed whether cannabis was less harmful than cigarettes and alcohol, he replied: "I think the scientific evidence is absolutely clear cut. I would agree with it."[63] A few days later, it was revealed that a leaked email from the government's Science MinisterLord Drayson was quoted as saying Mr Johnson's decision to dismiss Nutt without consulting him was a "big mistake" that left him "pretty appalled".[64]
On 4 November, the BBC reported that Nutt had financial backing to create a new independent drug research body if the ACMD was disbanded or proved incapable of functioning.[65] This new body, theIndependent Scientific Committee on Drugs (later renamed DrugScience), was launched in January 2010 (later on to establish, in 2013, the journalDrug Science, Policy and Law). On 10 November 2009, after a meeting between ACMD and Alan Johnson, three other scientists tendered their resignations, DrSimon Campbell, a chemist, psychologist DrJohn Marsden and scientific consultant Ian Ragan.[66]
In an 11 November 2009 editorial inThe Lancet, Nutt explicitly attributed his dismissal to a conflict between government and science, and reiterated that "I have repeatedly stated [cannabis] is not safe, but that the idea that you can reduce use through raising the classification in the Misuse of Drugs Act from class C to class B—where it had previously been placed, but thus now increasing the maximum penalty for possession for personal use to 5 years in prison—is implausible."[67] In a rejoinder, William Cullerne Bown ofResearch Fortnight pointed out that the framing of science vs. government was misleading because the weighting of the factors in Nutt's 2007Lancet paper was arbitrary, and consequently that there was no scientific answer to ranking drugs.[68] In reply, Nutt admitted the limitations of the original study, and wrote that ACMD was in the process of devising a multicriteria decision-making approach when he was dismissed. Nutt reiterated that "The repeated claims by Gordon Brown's government that it had scientific evidence that trumped that of the ACMD and the acknowledgment that it was only interested in scientific evidence that supported its political aims was a cynical misuse of scientific evidence that breached the principles of the1971 Act and was insulting to Council." Nutt announced that he and number of colleagues that had resigned from the ACMD had set up an Independent Scientific Committee on Drugs.[18]
A subsequent review of policy drafted byLord Drayson[18] essentially reaffirmed that the scientific advisers to the government can be dismissed under similar circumstances: "Government and its scientific advisers should not act to undermine mutual trust."[69] This clause was kept despite protest fromSense about Science,Campaign for Science and Engineering, and Liberal Democrat MPEvan Harris; according to Lord Drayson, the clause was requested byJohn Beddington, theChief Scientific Adviser to the UK Government.[70]Leslie Iversen was announced as the successor of Nutt as the chair of the ACMD in January 2010.[71]
David Nutt is aFellow of theRoyal College of Physicians,Royal College of Psychiatrists and theAcademy of Medical Sciences. He holds visiting professorships in Australia, New Zealand and the Netherlands. He is a past president of the British Association of Psychopharmacology and of the European College of Neuropsychopharmacology.[13] He was the recipient of the 2013John Maddox Prize for promoting sound science and evidence on a matter of public interest, whilst facing difficulty or hostility in doing so.[72] He is past president of the British Neuroscience Association and past president of theEuropean Brain Council.[73]
His bookDrugs Without the Hot Air (UIT press) won the Salon London Transmission Prize in 2014.[74]
TheUniversity of Bath awarded Nutt with anhonorary doctorate of laws in December 2019.[75]
David Nutt lives in Bristol, with his wife Diana. He has four children.[76]
Nutt is a Patron ofMy Death My Decision, an organisation which seeks a more compassionate approach to dying in the UK, including the legal right to a medically assisted death, if that is a person's persistent wish.[77]
Pharmacotherapy
Brain science
Addiction and associated disorder
Anxiety disorders
Other disorders
Sleep and connected disorder
{{cite book}}:|journal= ignored (help) (PMC link is a 2-page book review)
| International | |
|---|---|
| National | |
| Academics | |
| Artists | |
| People | |
| Other | |